Durability of Antiretroviral Suppression and the Real World Clinical Profile of the Novel 2‐Drug Regimen Juluca, a Onepill‐Regimen Consisting of Dolutegravir and Rilpivirine, in Routine Clinical Care in Germany
Phase of Trial: Phase IV
Latest Information Update: 11 Oct 2018
At a glance
- Drugs Dolutegravir/rilpivirine (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms JUNGLE
- Sponsors ViiV Healthcare
- 25 Jul 2018 Status changed from not yet recruiting to recruiting.
- 02 Jul 2018 Planned initiation date changed from 6 Jun 2018 to 6 Jul 2018.
- 11 May 2018 New trial record